Nelson Kopyt is a Nephrology physician affiliated with Lehigh Valley Health Network. OpenAlex indexes 60 publications with 2,543 citations (h-index 21); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1230 S Cedar Crest Blvd Stes 301, 302, 304
Allentown, PA 181036367
Telephone
610-432-4529Provider last certified this registry record 31 May 2022.
Clinical trials
- Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
Sponsor: Palladio Biosciences
Overall officialPhase 3TerminatedNCT05208866 - Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
Sponsor: Elcelyx Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ardelyx, Inc.Program year202567 payments$71,608openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year202535 payments$37,224openpaymentsdata.cms.gov ↗
- Vifor Pharma, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.7%Angiotensin receptor blocker (ARB)24.8%Losartan Potassium55%Valsartan26%Candesartan Cilexetil14%Irbesartan6%Part D<11 patientsCalcium channel blocker9.5%Amlodipine Besylate86%Diltiazem 24hr Er (Cd)14%Part D<11 patients+ 9 more classes in this area
Metabolism & gastrointestinal
18%SGLT2 inhibitor12.1%Farxiga83%Jardiance17%Part D<11 patientsH2 blocker2.2%Famotidine100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
8%Xanthine oxidase inhibitor8%Allopurinol100%Part D≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Annals of Internal Medicine
2023 - Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
American Journal of Kidney Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Friel, MD
Lehigh Valley Health Network
Armaan Dhaliwal
Lehigh Valley Health Network
Negar Moheb, MD
Lehigh Valley Health Network
Sharon Maynard, MD
Lehigh Valley Health Network
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”